

## Retatrutide

GLP-1 • 50mg • Research Use Only

### 1. SAMPLE IDENTIFICATION

|              |               |                 |                    |
|--------------|---------------|-----------------|--------------------|
| Product      | Retatrutide   | Batch / Lot no. | GP26-2201          |
| Category     | GLP-1         | Strength        | 50mg               |
| Presentation | Research Vial | Dosage form     | Lyophilised Powder |

### 2. IDENTITY CONFIRMATION

|                               |                   |                                |                                |
|-------------------------------|-------------------|--------------------------------|--------------------------------|
| Method                        | LC-MS (ESI-Q-TOF) | Result                         | Conforms to reference standard |
| [M+H] <sup>+</sup> observed   | 3164.9 m/z        | [M+H] <sup>+</sup> theoretical | 3165.1 m/z                     |
| [M+2H] <sup>2+</sup> observed | 1583.1 m/z        | Mass deviation                 | -0.2 Da                        |

### 3. PURITY AND QUANTITATIVE CONTENT

|                        |                                  |                           |                    |
|------------------------|----------------------------------|---------------------------|--------------------|
| Technique              | HPLC                             | Method                    | RP-HPLC-UV, 214 nm |
| Chromatographic purity | 98.8 % (area normalisation)      | Content, % of label claim | 100.1 %            |
| Measured content       | 50.05 mg/vial (label claim 50mg) |                           |                    |

### 4. ANALYTICAL DATA




Fig. 1 — HPLC chromatogram; main peak 6.50 min, 98.8% area.




Fig. 2 — ESI-Q-TOF mass spectrum; base peak [M+H]<sup>+</sup> 3164.9 m/z.

#### RESULT

**PASS — Identity conforms; chromatographic purity 98.8%**

### 5. AUTHORISATION AND VERIFICATION

|              |                  |                     |                                   |
|--------------|------------------|---------------------|-----------------------------------|
| Analyst      | Dr. R. Okonkwo   | Approved (QA)       | Dr. N. Kowalski                   |
| Date of test | 4 September 2026 | Date of manufacture | 19 August 2026                    |
| Expiry       | 19 August 2029   | Laboratory          | Puralytix Analytical Laboratories |

#### Verify this certificate

Report ID: **GP26-2201**

Verification key: **B3TX-8CSN**

[puralytix.com/report-verification](https://puralytix.com/report-verification)

Enter the report ID and verification key on the page above, or scan the QR code, to confirm this certificate is genuine.



Scan to verify

Puralytix Analytical Laboratories provides independent analytical testing and informational reports only. This certificate relates solely to the sample identified above and to the test methods stated. Results are subject to the inherent limitations and detection thresholds of the methods used. Puralytix does not provide medical, dosing, sourcing, legal or consumption advice, and no result implies that any substance is safe, approved, lawful or suitable for human use. **For research use only.** Clients are responsible for complying with the laws of their own jurisdiction. This document may not be reproduced except in full.

Puralytix Analytical Laboratories — 71 Vazha-Pshavela Avenue, Block 2, Saburtalo District, 0186 Tbilisi, Georgia • PLX-202609-50201